1. Home
  2. BMY
  3. BMY News

Latest Bristol-Myers Squibb Company (BMY) News on October 9, 2025

Should You Be Impressed By Bristol-Myers Squibb Company's (NYSE:BMY) ROE?
BMY

Simply Wall St.

2 days ago

Should You Be Impressed By Bristol-Myers Squibb Company's (NYSE:BMY) ROE?

Biotech Stocks Are Up. The Sector Is Looking Better Than It Has in Years.
BMY

Barrons.com

3 days ago

Biotech Stocks Are Up. The Sector Is Looking Better Than It Has in Years.

Investing Smart: Bristol-Myers Squibb (BMY) Among the Best Affordable Dividend Stocks
BMY

Insider Monkey

3 days ago

Investing Smart: Bristol-Myers Squibb (BMY) Among the Best Affordable Dividend Stocks

How Investors Are Reacting To Veeva Systems (VEEV) Winning Bristol Myers Squibb as a Vault CRM Client
BMY

Simply Wall St.

5 days ago

How Investors Are Reacting To Veeva Systems (VEEV) Winning Bristol Myers Squibb as a Vault CRM Client

Hon Hai Technology Group (Foxconn) Chief Procurement Officer Honored In Alcott Global's Top 30 Supply Chain Leaders of 2025
BMY

PR Newswire

6 days ago

Hon Hai Technology Group (Foxconn) Chief Procurement Officer Honored In Alcott Global's Top 30 Supply Chain Leaders of 2025

Bristol-Myers Squibb, Takeda, Astex Join AI Consortium to Train OpenFold3 for Accelerated Drug Discovery
BMY

Insider Monkey

6 days ago

Bristol-Myers Squibb, Takeda, Astex Join AI Consortium to Train OpenFold3 for Accelerated Drug Discovery

Bristol-Myers Squibb (BMY) Is Up 7.4% After FDA Fast Track Win for Alzheimer’s Drug Candidate
BMY

Simply Wall St.

7 days ago

Bristol-Myers Squibb (BMY) Is Up 7.4% After FDA Fast Track Win for Alzheimer’s Drug Candidate

Can Novo Nordisk's Restructuring Program Drive its Return to Growth?
BMY

Zacks

7 days ago

Can Novo Nordisk's Restructuring Program Drive its Return to Growth?

Bristol Myers Alzheimer's Drug Earns FDA Fast Track
BMY

GuruFocus.com

7 days ago

Bristol Myers Alzheimer's Drug Earns FDA Fast Track

Can CYTK Clinch a Potential FDA Nod for Its Cardiovascular Drug?
BMY

Zacks

7 days ago

Can CYTK Clinch a Potential FDA Nod for Its Cardiovascular Drug?

BMY

MT Newswires

7 days ago

Kinaxis to Deploy Maestro Platform for Sweden's Sobi to Boost Rare Disease Supply Chains

Chinese healthcare, biotech firms flock to Hong Kong for IPOs
BMY

South China Morning Post

7 days ago

Chinese healthcare, biotech firms flock to Hong Kong for IPOs

Bristol-Myers Squibb (BMY) Reports Strong Multiple Myeloma Data
BMY

Insider Monkey

7 days ago

Bristol-Myers Squibb (BMY) Reports Strong Multiple Myeloma Data

Bristol-Myers Squibb Company (BMY) Begins Selling Its Psoriasis Medication Sotyktu Directly to Cash-Paying U.S. Customers
BMY

Insider Monkey

8 days ago

Bristol-Myers Squibb Company (BMY) Begins Selling Its Psoriasis Medication Sotyktu Directly to Cash-Paying U.S. Customers

Prothena’s Partner Bristol Myers Squibb Obtains Fast Track Designation from the U.S. FDA for BMS-986446 (PRX005), an Anti-MTBR-Tau-Targeting Antibody, for the Treatment of Alzheimer’s Disease
BMY

Business Wire

8 days ago

Prothena’s Partner Bristol Myers Squibb Obtains Fast Track Designation from the U.S. FDA for BMS-986446 (PRX005), an Anti-MTBR-Tau-Targeting Antibody, for the Treatment of Alzheimer’s Disease

BMY

MT Newswires

8 days ago

Sector Update: Health Care Stocks Rise Late Afternoon

Trump Triggered a Rally in Drug Stocks. Why It Might Not Last.
BMY

Barrons.com

8 days ago

Trump Triggered a Rally in Drug Stocks. Why It Might Not Last.

BMY

MT Newswires

8 days ago

Sector Update: Health Care Stocks Mixed Premarket Wednesday

BMY

MT Newswires

8 days ago

Sector Update: Health Care

BMY

MT Newswires

8 days ago

Bristol-Myers Receives FDA Fast Track Designation for Early Alzheimer's Drug

BMY

MT Newswires

8 days ago

Bristol-Myers Squibb, Takeda Join Apheris' OpenFold3 Drug Discovery AI Model

Bristol Myers Squibb’s Anti-MTBR-Tau-Targeting Antibody, BMS-986446, Granted Fast Track Designation by U.S. FDA for the Treatment of Alzheimer’s Disease
BMY

Business Wire

8 days ago

Bristol Myers Squibb’s Anti-MTBR-Tau-Targeting Antibody, BMS-986446, Granted Fast Track Designation by U.S. FDA for the Treatment of Alzheimer’s Disease

Bristol Myers, Takeda to pool data for AI-based drug discovery
BMY

Reuters

8 days ago

Bristol Myers, Takeda to pool data for AI-based drug discovery

What TrumpRx Means For Controversial Plan To Lower U.S. Drug Prices
BMY

Investor's Business Daily

9 days ago

What TrumpRx Means For Controversial Plan To Lower U.S. Drug Prices

Bristol Myers Squibb (BMY) Beats Stock Market Upswing: What Investors Need to Know
BMY

Zacks

9 days ago

Bristol Myers Squibb (BMY) Beats Stock Market Upswing: What Investors Need to Know

Bristol-Myers Squibb Company (BMY) to Capitalize on Cell Therapy Edge to Pursue CAR-T Treatment Opportunities
BMY

Insider Monkey

9 days ago

Bristol-Myers Squibb Company (BMY) to Capitalize on Cell Therapy Edge to Pursue CAR-T Treatment Opportunities

How Bristol-Myers Squibb Company (BMY) Delivers Strong Yields Even in Tough Markets
BMY

Insider Monkey

10 days ago

How Bristol-Myers Squibb Company (BMY) Delivers Strong Yields Even in Tough Markets

AbbVie to launch ovarian cancer drug in UK at US price
BMY

Reuters

10 days ago

AbbVie to launch ovarian cancer drug in UK at US price

Bristol Myers Squibb Company (BMY) Is a Trending Stock: Facts to Know Before Betting on It
BMY

Zacks

10 days ago

Bristol Myers Squibb Company (BMY) Is a Trending Stock: Facts to Know Before Betting on It

A Fresh Look at Bristol Myers Squibb’s Valuation Following Its Patient Connect Expansion and Drug Discount Initiative
BMY

Simply Wall St.

11 days ago

A Fresh Look at Bristol Myers Squibb’s Valuation Following Its Patient Connect Expansion and Drug Discount Initiative

Why Bristol-Myers Squibb (BMY) Deserves a Spot in Passive Income Portfolios
BMY

Insider Monkey

12 days ago

Why Bristol-Myers Squibb (BMY) Deserves a Spot in Passive Income Portfolios

AstraZeneca to Offer Discounted Drugs As Trump Pressures Pharma Industry to Cut Prices
BMY

The Wall Street Journal

13 days ago

AstraZeneca to Offer Discounted Drugs As Trump Pressures Pharma Industry to Cut Prices

MRK vs. BMY: Which Pharma Stock Is the Smarter Pick Now?
BMY

Zacks

13 days ago

MRK vs. BMY: Which Pharma Stock Is the Smarter Pick Now?

Trump’s overnight demand for 100% tariffs on pharmaceuticals will be ‘a meaningful commercial hit for U.S. consumers,’ top analyst says
BMY

Fortune

13 days ago

Trump’s overnight demand for 100% tariffs on pharmaceuticals will be ‘a meaningful commercial hit for U.S. consumers,’ top analyst says

These Stocks Are Moving the Most Today: Eli Lilly, Wayfair, Intel, Oracle, Concentrix, Costco, and More
BMY

Barrons.com

13 days ago

These Stocks Are Moving the Most Today: Eli Lilly, Wayfair, Intel, Oracle, Concentrix, Costco, and More

Is pharma’s IRA pricing battle running out of steam?
BMY

Pharma Voice

13 days ago

Is pharma’s IRA pricing battle running out of steam?

Trump Plans New Tariff Push With 100% Rate on Patented Drugs
BMY

Bloomberg

13 days ago

Trump Plans New Tariff Push With 100% Rate on Patented Drugs

US, European pharma stocks steady after Trump's tariff move, Asia slips
BMY

Reuters

13 days ago

US, European pharma stocks steady after Trump's tariff move, Asia slips

BMS expands DTC offering with Sotyktu addition
BMY

Pharmaceutical Technology

14 days ago

BMS expands DTC offering with Sotyktu addition

PGIM Jennison Health Sciences Fund Sold its Position in Bristol-Myers Squibb Co. (BMY) in Q2
BMY

Insider Monkey

14 days ago

PGIM Jennison Health Sciences Fund Sold its Position in Bristol-Myers Squibb Co. (BMY) in Q2

BMY

MT Newswires

14 days ago

Bristol-Myers Squibb to Offer Sotyktu, Eliquis Drugs at 'Steeply Discounted Prices' to Eligible US Patients

Bristol Myers Squibb Builds on Eliquis® (apixaban) Direct-to-Patient Program, Announces New BMS Patient Connect Platform Offering Sotyktu® (deucravacitinib)
BMY

Business Wire

14 days ago

Bristol Myers Squibb Builds on Eliquis® (apixaban) Direct-to-Patient Program, Announces New BMS Patient Connect Platform Offering Sotyktu® (deucravacitinib)

Bristol Myers Squibb (BMY) Registers a Bigger Fall Than the Market: Important Facts to Note
BMY

Zacks

15 days ago

Bristol Myers Squibb (BMY) Registers a Bigger Fall Than the Market: Important Facts to Note

REPL Stock Plunges 54% in 3 Months After FDA Rejects Skin Cancer Drug
BMY

Zacks

15 days ago

REPL Stock Plunges 54% in 3 Months After FDA Rejects Skin Cancer Drug

BMY Reports Positive Data From a Late-Stage Multiple Myeloma Study
BMY

Zacks

15 days ago

BMY Reports Positive Data From a Late-Stage Multiple Myeloma Study

The Smartest Dividend Stock to Buy With $1,000 Right Now
BMY

Motley Fool

15 days ago

The Smartest Dividend Stock to Buy With $1,000 Right Now

SystImmune, Inc. to Present New Clinical Data on Izalontamab Brengitecan and BL-M07D1 Highlighting Strength of Differentiated Antibody Drug Conjugate (ADC) Platform
BMY

PR Newswire

15 days ago

SystImmune, Inc. to Present New Clinical Data on Izalontamab Brengitecan and BL-M07D1 Highlighting Strength of Differentiated Antibody Drug Conjugate (ADC) Platform

BMY

Morningstar Research

15 days ago

Analyst Report: Bristol-Myers Squibb Company

Bristol-Myers Squibb Company (BMY) to Divest 60% China JV Amid Strategic Realignment
BMY

Insider Monkey

16 days ago

Bristol-Myers Squibb Company (BMY) to Divest 60% China JV Amid Strategic Realignment

BMY

MT Newswires

16 days ago

Bristol-Myers Says Potential Multiple Myeloma Treatment Showed 'Statistically Significant Improvement' in Phase 3 Trial

Bristol Myers says next-gen blood cancer drug hits goal in key study
BMY

BioPharma Dive

16 days ago

Bristol Myers says next-gen blood cancer drug hits goal in key study

Bristol Myers Squibb Announces Phase 3 EXCALIBER-RRMM Study Evaluating Iberdomide in Combination with Standard Therapies Demonstrated a Significant Improvement in Minimal Residual Disease Negativity Rates in Relapsed or Refractory Multiple Myeloma
BMY

Business Wire

16 days ago

Bristol Myers Squibb Announces Phase 3 EXCALIBER-RRMM Study Evaluating Iberdomide in Combination with Standard Therapies Demonstrated a Significant Improvement in Minimal Residual Disease Negativity Rates in Relapsed or Refractory Multiple Myeloma

Bull of the Day: Halozyme Therapeutics (HALO)
BMY

Zacks

16 days ago

Bull of the Day: Halozyme Therapeutics (HALO)

1 Reason to Buy Bristol Myers Squibb Stock
BMY

Motley Fool

16 days ago

1 Reason to Buy Bristol Myers Squibb Stock

Bristol Myers Squibb Commits to Veeva Vault CRM
BMY

PR Newswire

17 days ago

Bristol Myers Squibb Commits to Veeva Vault CRM

MapLight lines up an IPO in bid to challenge Bristol Myers schizophrenia drug
BMY

BioPharma Dive

17 days ago

MapLight lines up an IPO in bid to challenge Bristol Myers schizophrenia drug

How To Put $100 In Your Retirement Fund Each Month With Bristol-Myers Squibb Stock
BMY

Benzinga

18 days ago

How To Put $100 In Your Retirement Fund Each Month With Bristol-Myers Squibb Stock

Should You Reconsider Bristol-Myers After Shares Drop 21% Amid Pharma Tariff Uncertainty?
BMY

Simply Wall St.

19 days ago

Should You Reconsider Bristol-Myers After Shares Drop 21% Amid Pharma Tariff Uncertainty?

Bristol-Myers Squibb Company’s (BMY) Dividend Track Record: A Must-Have for a Dividend Stock Portfolio
BMY

Insider Monkey

20 days ago

Bristol-Myers Squibb Company’s (BMY) Dividend Track Record: A Must-Have for a Dividend Stock Portfolio

US Weighs Trump-Branded Website to Help Shop for Cheaper Drugs
BMY

Bloomberg

20 days ago

US Weighs Trump-Branded Website to Help Shop for Cheaper Drugs

Can Bristol Myers Squibb's Restructuring Program Boost Earnings Growth?
BMY

Zacks

20 days ago

Can Bristol Myers Squibb's Restructuring Program Boost Earnings Growth?

Bristol Myers Squibb to Report Results for Third Quarter 2025 on October 30, 2025
BMY

Business Wire

20 days ago

Bristol Myers Squibb to Report Results for Third Quarter 2025 on October 30, 2025

Bristol Myers Squibb (BMY) Stock Sinks As Market Gains: What You Should Know
BMY

Zacks

21 days ago

Bristol Myers Squibb (BMY) Stock Sinks As Market Gains: What You Should Know

BMY

MT Newswires

21 days ago

Alnylam Joins Alliance for Genomic Discovery

Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
BMY

Zacks

21 days ago

Are You a Value Investor? This 1 Stock Could Be the Perfect Pick

Global Cell Therapy Market Size Expected to Reach $44 Billion as Demand for Regenerative Medicine Rises
BMY

CNW Group

21 days ago

Global Cell Therapy Market Size Expected to Reach $44 Billion as Demand for Regenerative Medicine Rises

Top Stock Reports for Exxon Mobil, AMD & Caterpillar
BMY

Zacks

22 days ago

Top Stock Reports for Exxon Mobil, AMD & Caterpillar

Advancing Cancer Research Brings New Hope for Patients Worldwide
BMY

CNW Group

22 days ago

Advancing Cancer Research Brings New Hope for Patients Worldwide

Bristol Myers Squibb Announces Dividend
BMY

Business Wire

22 days ago

Bristol Myers Squibb Announces Dividend

Bristol Myers to sell 60% stake in China joint venture
BMY

Reuters

22 days ago

Bristol Myers to sell 60% stake in China joint venture

What Does Wall Street Think About Bristol-Myers Squibb (BMY)?
BMY

Insider Monkey

23 days ago

What Does Wall Street Think About Bristol-Myers Squibb (BMY)?

Bristol-Myers Squibb Company (BMY)-BioNTech Lung Cancer Therapy Shows 76% Tumor Reduction
BMY

Insider Monkey

23 days ago

Bristol-Myers Squibb Company (BMY)-BioNTech Lung Cancer Therapy Shows 76% Tumor Reduction

These 4 Measures Indicate That Bristol-Myers Squibb (NYSE:BMY) Is Using Debt Reasonably Well
BMY

Simply Wall St.

23 days ago

These 4 Measures Indicate That Bristol-Myers Squibb (NYSE:BMY) Is Using Debt Reasonably Well

K36 Therapeutics Provides Clinical Update on KTX-1001 in Multiple Myeloma
BMY

PR Newswire

23 days ago

K36 Therapeutics Provides Clinical Update on KTX-1001 in Multiple Myeloma

Bristol Myers Squibb to Participate in the Bernstein Insights: Healthcare Leaders and Disruptors - 2nd Annual Healthcare Forum
BMY

Business Wire

23 days ago

Bristol Myers Squibb to Participate in the Bernstein Insights: Healthcare Leaders and Disruptors - 2nd Annual Healthcare Forum

Press Release Biocartis NV: Biocartis Receives FDA Approval for the Idylla™ CDx MSI Test
BMY

GlobeNewswire

24 days ago

Press Release Biocartis NV: Biocartis Receives FDA Approval for the Idylla™ CDx MSI Test

Perspective Therapeutics Progresses Dose Finding for [212Pb]VMT01 in Combination with Nivolumab in its Ongoing Phase 1/2a Study of MC1R-Positive Metastatic Melanoma
BMY

GlobeNewswire

24 days ago

Perspective Therapeutics Progresses Dose Finding for [212Pb]VMT01 in Combination with Nivolumab in its Ongoing Phase 1/2a Study of MC1R-Positive Metastatic Melanoma

How Bad Is This Sector’s Health Scare?
BMY

The Wall Street Journal

24 days ago

How Bad Is This Sector’s Health Scare?

BioNTech (BNTX) Faces Legal Challenges Over mRNA Patent
BMY

Simply Wall St.

a month ago

BioNTech (BNTX) Faces Legal Challenges Over mRNA Patent

Pfizer's Late-Stage Pipeline Fuels Long-Term Growth Prospects
BMY

Zacks

a month ago

Pfizer's Late-Stage Pipeline Fuels Long-Term Growth Prospects

BMY-BioNTech Partnership: A Potential Catalyst for Long-Term Gains?
BMY

Zacks

a month ago

BMY-BioNTech Partnership: A Potential Catalyst for Long-Term Gains?

Bristol Myers Squibb Company (BMY) is Attracting Investor Attention: Here is What You Should Know
BMY

Zacks

a month ago

Bristol Myers Squibb Company (BMY) is Attracting Investor Attention: Here is What You Should Know

Pfizer Is Growing More Reliant on Vaccines as Controversies Swirl
BMY

Barrons.com

a month ago

Pfizer Is Growing More Reliant on Vaccines as Controversies Swirl

3 Reasons to Sell BMY and 1 Stock to Buy Instead
BMY

StockStory

a month ago

3 Reasons to Sell BMY and 1 Stock to Buy Instead

Bristol Myers Squibb, BioNTech Announce Positive Interim Data from Phase 2 Trial of Pumitamig in Lung Cancer
BMY

Insider Monkey

a month ago

Bristol Myers Squibb, BioNTech Announce Positive Interim Data from Phase 2 Trial of Pumitamig in Lung Cancer

BMO Capital Maintains a Hold on Bristol-Myers Squibb Company (BMY)
BMY

Insider Monkey

a month ago

BMO Capital Maintains a Hold on Bristol-Myers Squibb Company (BMY)

Prothena Down 40% Year to Date: What Lies Ahead for the Stock?
BMY

Zacks

a month ago

Prothena Down 40% Year to Date: What Lies Ahead for the Stock?

Bristol Myers Loses 19.2% in Six Months: Buy, Sell or Hold?
BMY

Zacks

a month ago

Bristol Myers Loses 19.2% in Six Months: Buy, Sell or Hold?

Bristol-Myers Squibb (BMY): Assessing Valuation After New Pipeline Updates and Growth Strategy Reveal
BMY

Simply Wall St.

a month ago

Bristol-Myers Squibb (BMY): Assessing Valuation After New Pipeline Updates and Growth Strategy Reveal

China’s Multibillion-Dollar US Pharma Pipeline Draws Scrutiny in Washington
BMY

The Daily Upside

a month ago

China’s Multibillion-Dollar US Pharma Pipeline Draws Scrutiny in Washington

Did Positive Lung Cancer Data Just Shift Bristol Myers Squibb’s (BMY) Pipeline and Innovation Narrative?
BMY

Simply Wall St.

a month ago

Did Positive Lung Cancer Data Just Shift Bristol Myers Squibb’s (BMY) Pipeline and Innovation Narrative?

Flputnam Lifts Stake in Bristol-Myers Squibb Company (BMY) by 52%
BMY

Insider Monkey

a month ago

Flputnam Lifts Stake in Bristol-Myers Squibb Company (BMY) by 52%

Bristol Myers Squibb (BMY) Outperforms Broader Market: What You Need to Know
BMY

Zacks

a month ago

Bristol Myers Squibb (BMY) Outperforms Broader Market: What You Need to Know

SMMT Stock Plummets 25% on Regional Data Differences in NSCLC Study
BMY

Zacks

a month ago

SMMT Stock Plummets 25% on Regional Data Differences in NSCLC Study

Idiopathic pulmonary fibrosis breakthroughs may lead to first drug approval in years
BMY

Clinical Trials Arena

a month ago

Idiopathic pulmonary fibrosis breakthroughs may lead to first drug approval in years

The Best Ultra-High-Yield Dividend Stock to Invest $1,000 in Right Now
BMY

Motley Fool

a month ago

The Best Ultra-High-Yield Dividend Stock to Invest $1,000 in Right Now

BMY

MT Newswires

a month ago

BioNTech, Bristol Myers Squibb Report Tumor Shrinkage in Phase 2 Pumitamig Study

First Disclosure of Global Interim Phase 2 Data for BioNTech and Bristol Myers Squibb PD-L1xVEGF-A Bispecific Antibody Pumitamig (BNT327/BMS986545) in Patients with Extensive-Stage Small Cell Lung Cancer Shows Encouraging Antitumor Activity
BMY

GlobeNewswire

a month ago

First Disclosure of Global Interim Phase 2 Data for BioNTech and Bristol Myers Squibb PD-L1xVEGF-A Bispecific Antibody Pumitamig (BNT327/BMS986545) in Patients with Extensive-Stage Small Cell Lung Cancer Shows Encouraging Antitumor Activity

Investing in Oncology: 3 Cancer Stocks With Promising Pipelines
BMY

Zacks

a month ago

Investing in Oncology: 3 Cancer Stocks With Promising Pipelines

Market’s In A Mood For Consolidaton When It Comes To The Hershey Company (HSY), Says Jim Cramer
BMY

Insider Monkey

a month ago

Market’s In A Mood For Consolidaton When It Comes To The Hershey Company (HSY), Says Jim Cramer

Share on Social Networks: